Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial
暂无分享,去创建一个
D. Atar | S. Solomon | M. Pfeffer | G. Filippatos | J. McMurray | J. Rouleau | L. Lund | J. Cleland | M. Senni | S. Anker | L. Køber | P. Seferovic | M. Lelonek | F. Zannad | B. Merkely | J. Widimský | M. Zile | B. Pieske | A. Maggioni | M. Packer | J. Ge | Chen-Huan Chen | G. Linssen | B. Oh | S. Janssens | S. Boytsov | D. Miličić | J. Gong | M. Lefkowitz | V. Shi | M. Galinier | D. V. van Veldhuisen | R. Zweiker | M. Redfield | B. Vrtovec | Sanjiv Shah | M. Yılmaz | E. O'meara | I. Anand | F. Martinez | A. Flammer | Yoshihiko Saito | C. Lam | D. Vinereanu | N. Sweitzer | N. Anavekar | V. Chopra | S. Perrone | D. Sim | J. L. Arango | A. Rizkala | J. Comín-Colet | Jingmin Zhou | T. Katova | J. Saraiva | Luis E. Echeverria Correa | N. Ranjith | J. Taurio | H. Duengen | A. Sibulo | E. Goncalvesova | T. Ben-Gal | J. L. Arenas | A. Godoy | E. O’Meara | Jyrki Taurio | Luis E. Echeverría Correa
[1] Roberto Ferrari,et al. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.
[2] Akshay S. Desai,et al. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.
[3] R. McKelvie,et al. Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. , 2015, JACC. Heart failure.
[4] S. Solomon,et al. International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction , 2015, Circulation.
[5] Akshay S. Desai,et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.
[6] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[7] M. Komajda,et al. Controversies in cardiovascular medicine Heart failure with preserved ejection fraction : a clinical dilemma , 2014 .
[8] Sanjiv J Shah,et al. Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.
[9] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[10] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[11] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[12] N. Freemantle,et al. FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .
[13] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[14] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.